Drug Discovery

WuXi AppTec has recently come under fire from U.S. politicians who want to ban government-backed projects from buying its services, causing the stock to lose about half of its value this year.

FAST NEWS: BlackRock boosts stake in battered WuXi AppTec

The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
2359.HK 603259.SHG
U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec for HK$75.33 million on Feb. 8.

FAST NEWS: JPMorgan boosts WuXi AppTec stake

The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
2359.HK 603259.SHG
Viva Biotech announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan has been completed.

FAST NEWS: Viva Biotech completes Langhua Pharma buyout

The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…

Recent Articles

RELATED ARTICLES

  1. WuXi Biologics
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  2. BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
    2359.HK 603259.SHG
  3. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  4. A Drug Company’s Forced Sales, and a Family Feud in Shanghai
    2269.HK 2359.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva